---
created: 2025-04-13
updated: 2025-04-13T10:53
id: k}K/A{G&8Q
specialty: patho
specialty_id: 134
tags:
  - source/ak-original-decks::step-1::zanki-step-decks::zanki-immunology-+-general-pathology::pathoma-chapter-3-(neoplasia)
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::14-p-glycoprotein
  - "source/ak-step1-v11:": 
  - theme/nbme::26
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia::01-neoplasia::bg-extras
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia-alt-tagging::bluegalaxies::extra
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::1000-1999::1819
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^fa-updates::fa2018
type: flashcard
---

# Question
P-glycoprotein, encoded by the **MDR1 multidrug resistance 1 gene**, is a transmembrane protein that functions as an ATP-dependent efflux pump == multidrug CTh resistance

---

# Answer
In TU cells, increased expression of P-glycoprotein == increase the efflux of numerous CTh agents from the cytosol, particularly hydrophobic ones (eg, doxorubicin, vincristine)   efflux pump normally used by gut and kidney to pump out toxins, TUs can use these to pump out chemotherapeutics  - In contrast, the MDR2 gene encodes for another efflux pump that the liver uses to excrete conjugated bilirubin / kidney uses to excrete toxins (defective in Dubin-Johnson syndrome)